Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Pharmacyclics Inc

+ Add to Watchlist

PCYC:US

254.2200 USD 23.7400 10.30%

As of 20:10:00 ET on 03/05/2015.

Snapshot for Pharmacyclics Inc (PCYC)

Open: 255.0000 Day's Range: 253.9850 - 255.5200 Volume: 18,698,868
Previous Close: 230.4800 52wk Range: 82.5100 - 255.5200 1-Yr Rtn: +87.53%

Stock Chart for PCYC

No chart data available.
  • PCYC:US 254.2800
  • 1D
  • 1M
  • 1Y
230.4800
Interactive PCYC Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for PCYC

Current P/E Ratio (ttm) 235.3889
Estimated P/E(12/2015) 213.9899
Relative P/E vs. SPX 12.5405
Earnings Per Share (USD) (ttm) 1.0800
Est. EPS (USD) (12/2015) 1.1880
Est. PEG Ratio 8.1573
Market Cap (M USD) 19,325.02
Shares Outstanding (M) 76.02
30 Day Average Volume 2,049,345
Price/Book (mrq) 23.2811
Price/Sale (ttm) 26.2558
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/01/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for PCYC

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for PCYC

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing innovative small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's pharmaceutical drug development candidates are synthetic small-molecules designed to target key biochemical pathways involved in human diseases with critical unmet needs.

Robert W Duggan "Bob"Chairman/CEOManmeet SoniCFO/Treasurer
Mahkam Zanganeh "Maky"Chief Operating OfficerShawn Cline TomaselloChief Commercial Officer
More Company Profile & Key Executives for PCYC

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil